This guideline covers diagnosing and managing hypertension (high blood pressure), including pre-eclampsia, during pregnancy, labour and birth. It also includes advice for women with hypertension who wish to conceive and women who have had a pregnancy complicated by hypertension. It aims to improve care during pregnancy, labour and birth for women and their babies.
In January 2011, a correction was made to recommendation 18.104.22.168 on the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs).
This guideline includes recommendations on:
- reducing the risk of hypertension in pregnancy
- managing chronic hypertension in pregnancy and gestational hypertension
- assessing proteinuria
- managing pre-eclampsia, including severe pre-eclampsia in critical care settings
- fetal monitoring and care of women during labour and birth
- advice and follow-up in community care
Who is it for?
- Healthcare professionals
- Women who develop hypertension during pregnancy, women who have hypertension and wish to conceive, and women who have had a pregnancy complicated by hypertension
Is this guideline up to date?
We checked this guideline in January 2017 and we are updating the recommendations on:
- management of pregnancy with chronic hypertension
- management of pregnancy with gestational hypertension
- management of pregnancy with pre-eclampsia
- advice and follow-up care at transfer to community care
See the guideline in development page for progress on the update.
Guideline development process
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.